The patent, titled “ALPHA-1062 for treating Traumatic Brain Injury,” strengthens Alpha Cognition’s existing portfolio supporting both ALPHA-1062 and ZUNVEYL
The acquisition adds VYKAT XR (diazoxide choline), the first FDA-approved therapy for hyperphagia in Prader-Willi syndrome (PWS), a rare genetic disorder, to Neurocrine’s portfolio
The new capital is expected to fund the company through 2029
Approval for 5 mg and 10 mg strengths, bioequivalent to Farxiga®, strengthens Lupin’s anti-diabetic portfolio in US market
The financing includes a four-year interest-only period, extendable to five years if a net sales milestone is achieved
Under the collaboration, Symeres will test Ambagon’s newly designed molecular glues using in vitro assays and mechanistic studies
The drug meets all primary endpoints across 608 patients in Europe and India, strengthening the company's biosimilars pipeline
The last-mile healthcare delivery across 1,100 villages, with focus on maternal health, diagnostics, and chronic disease management
Veteran HR leader comes with over two decades of experience to spearhead talent strategy, leadership development, and culture transformation
As part of the deal, Red Nucleus also gains indirect ownership of the company’s Indian arm
Subscribe To Our Newsletter & Stay Updated
